Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening
Author:
Funder
Fundacja na rzecz Nauki Polskiej
Narodowe Centrum Nauki
Publisher
Elsevier BV
Subject
Electrochemistry,Biomedical Engineering,General Medicine,Biophysics,Biotechnology
Reference127 articles.
1. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data;Aguiar;Immunotherapy,2017
2. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma;Ahmed;Expet Rev. Clin. Pharmacol.,2019
3. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy;Ai;Drug Des. Dev. Ther.,2020
4. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics;Akinleye;J. Hematol. Oncol.,2019
5. FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis;Arora;Clin. Cancer Res.,2020
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Trends in electrochemical biosensors for the early diagnosis of breast cancer through the detection of relevant biomarkers;Chemical Physics Impact;2024-06
2. Optimizing drug discovery: Surface plasmon resonance techniques and their multifaceted applications;Chemical Physics Impact;2024-06
3. One-step and label-free ratiometric fluorescence assay for the detection of plasma exosome towards cancer diagnosis;Talanta;2024-05
4. Research Progress of PD-1/PD-L1 Signaling Pathway in Esophageal Squamous Cell Carcinoma;Advances in Clinical Medicine;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3